This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $1,930,758 to Sylvatica Biotech Inc., a minority-owned small business, to develop novel techniques for "enhanced supercooling" to enable ice-free preservation of clinical-scale livers at high subzero temperatures for over 72 hours. The goal is to significantly extend current liver preservation times...
This federal Project Grant award from the National Science Foundation (NSF) Engineering program (CFDA 47.041) provides $199,867 to the University of Washington to develop an innovative approach for long-term cryopreservation of organs using ice-free vitrification and single-mode electromagnetic resonance (SMER) heating. The project aims to overcome barriers in organ cryopreservation by advancing vitrification and EM heating technologies to enable fast and uniform rewarming of cryopreserved...
This federal Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $940,821 to Cryocrate LLC, a for-profit biotech company based in Columbia, Missouri, to develop a first-in-class biocompatible and efficient cryopreservation technology platform for cell-based therapeutics in regenerative medicine and drug discovery. The key objectives of this project are: (I) Producing the company's proprietary Odinsol cryopreservation medium...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK - CFDA 93.847) to Biomedinnovations, Inc. (BMI Organbank) will fund the development of a platform for extended kidney preservation via subnormothermic perfusion. The $3,740,270 award, effective September 20, 2024 through June 30, 2026, aims to optimize BMI's perfusion device and perfusate, evaluate the impact of warm ischemic injury and preservation duration, and compare the function of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $3,367,846 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nour Heart Inc. to develop a novel bioenergetic drug called Nourexal (cyclocreatine phosphate, or CCRP) to increase donor heart utilization. The goal is to extend the time and distance that donor hearts can be transported, which could potentially increase heart transplant cases by over 3,000 per year. The 2-year project aims to: 1) produce...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) provides $889,188 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a new intravenous oxygen (IVO2) therapy for early resuscitation of cardiac arrest. The project aims to optimize the polymeric microbubble carrier for IVO2 to accelerate clearance and minimize long-term toxicity, further evaluate the physiologic...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $350,000 Project Grant to Karios Technologies LLC to develop TissueShield, a novel single-use, ready-to-use, sterile, dual-chamber, dual-syringe sprayable hydrogel for preventing post-surgical cardiac adhesions. TissueShield is a 3-component polymer system that can be easily sprayed directly onto the heart, forming a robust anti-adhesion layer within seconds. The...
This federal Project Grant award, titled "Noninvasive Optical Assessment of Neuroprotection in Deep Hypothermic Circulatory Arrest Procedures", is funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $630,982 award, granted on May 6, 2025 and running through February 28, 2030, supports a comprehensive study led by The General Hospital Corporation...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $793,956 Project Grant to Resuscitation Innovations LLC, dba Advancedcpr Solutions LLC, to develop improved treatments for refractory cardiac arrest. The goal is to research and develop "head up CPR and aortic occlusion" techniques to significantly improve survival rates for the over 750,000 US patients annually who do not recover from cardiac arrest...